JP2017533243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533243A5 JP2017533243A5 JP2017524450A JP2017524450A JP2017533243A5 JP 2017533243 A5 JP2017533243 A5 JP 2017533243A5 JP 2017524450 A JP2017524450 A JP 2017524450A JP 2017524450 A JP2017524450 A JP 2017524450A JP 2017533243 A5 JP2017533243 A5 JP 2017533243A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- hlb value
- nonionic surfactant
- carrier material
- hydrophobic carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002736 nonionic surfactant Substances 0.000 claims 31
- 239000012051 hydrophobic carrier Substances 0.000 claims 20
- 239000000463 material Substances 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 12
- 239000002539 nanocarrier Substances 0.000 claims 11
- 229920001600 hydrophobic polymer Polymers 0.000 claims 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 150000002191 fatty alcohols Chemical class 0.000 claims 4
- 238000001914 filtration Methods 0.000 claims 4
- 229920000728 polyester Polymers 0.000 claims 4
- -1 sorbitan ester Chemical class 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 239000004632 polycaprolactone Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 1
- HBOQXIRUPVQLKX-BBWANDEASA-N 1,2,3-trilinoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)COC(=O)CCCCCCC\C=C/C\C=C/CCCCC HBOQXIRUPVQLKX-BBWANDEASA-N 0.000 claims 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
- MGYUQZIGNZFZJS-KTKRTIGZSA-N 2-[2-[(z)-octadec-9-enoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCO MGYUQZIGNZFZJS-KTKRTIGZSA-N 0.000 claims 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 229920002415 Pluronic P-123 Polymers 0.000 claims 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 claims 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000002563 ionic surfactant Substances 0.000 claims 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims 1
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- 229940055577 oleyl alcohol Drugs 0.000 claims 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001440 poly(ε-caprolactone)-block-poly(ethylene glycol) Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021080003A JP7827412B2 (ja) | 2014-11-05 | 2021-05-10 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
| JP2023109379A JP2023169893A (ja) | 2014-11-05 | 2023-07-03 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075866P | 2014-11-05 | 2014-11-05 | |
| US201462075864P | 2014-11-05 | 2014-11-05 | |
| US62/075,866 | 2014-11-05 | ||
| US62/075,864 | 2014-11-05 | ||
| PCT/US2015/059349 WO2016073798A1 (en) | 2014-11-05 | 2015-11-05 | Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021080003A Division JP7827412B2 (ja) | 2014-11-05 | 2021-05-10 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533243A JP2017533243A (ja) | 2017-11-09 |
| JP2017533243A5 true JP2017533243A5 (enExample) | 2018-12-13 |
| JP6912377B2 JP6912377B2 (ja) | 2021-08-04 |
Family
ID=54697646
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017524451A Active JP7218089B2 (ja) | 2014-11-05 | 2015-11-05 | 安定した過飽和状態でラパマイシンをもつ合成ナノキャリアに関する方法および組成物 |
| JP2017524450A Active JP6912377B2 (ja) | 2014-11-05 | 2015-11-05 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
| JP2021080003A Active JP7827412B2 (ja) | 2014-11-05 | 2021-05-10 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
| JP2022139392A Pending JP2022173236A (ja) | 2014-11-05 | 2022-09-01 | 安定した過飽和状態でラパマイシンをもつ合成ナノキャリアに関する方法および組成物 |
| JP2023109379A Pending JP2023169893A (ja) | 2014-11-05 | 2023-07-03 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017524451A Active JP7218089B2 (ja) | 2014-11-05 | 2015-11-05 | 安定した過飽和状態でラパマイシンをもつ合成ナノキャリアに関する方法および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021080003A Active JP7827412B2 (ja) | 2014-11-05 | 2021-05-10 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
| JP2022139392A Pending JP2022173236A (ja) | 2014-11-05 | 2022-09-01 | 安定した過飽和状態でラパマイシンをもつ合成ナノキャリアに関する方法および組成物 |
| JP2023109379A Pending JP2023169893A (ja) | 2014-11-05 | 2023-07-03 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20160128987A1 (enExample) |
| EP (6) | EP4360633A3 (enExample) |
| JP (5) | JP7218089B2 (enExample) |
| KR (2) | KR102656139B1 (enExample) |
| CN (5) | CN107072964A (enExample) |
| AU (4) | AU2015342968B2 (enExample) |
| BR (3) | BR122021025344B1 (enExample) |
| CA (2) | CA2966852C (enExample) |
| CY (1) | CY1124418T1 (enExample) |
| DK (4) | DK3215133T3 (enExample) |
| EA (2) | EA201790977A1 (enExample) |
| ES (4) | ES2977259T3 (enExample) |
| FI (2) | FI3834823T3 (enExample) |
| HR (1) | HRP20210098T1 (enExample) |
| HU (4) | HUE054894T2 (enExample) |
| IL (7) | IL296246A (enExample) |
| LT (1) | LT3215133T (enExample) |
| MX (4) | MX383295B (enExample) |
| PL (1) | PL3215133T3 (enExample) |
| PT (1) | PT3215133T (enExample) |
| RS (1) | RS61359B1 (enExample) |
| SI (1) | SI3215133T1 (enExample) |
| WO (2) | WO2016073798A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138193A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| CN107320734A (zh) | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| WO2015025538A1 (ja) * | 2013-08-20 | 2015-02-26 | サンノプコ株式会社 | バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法 |
| EA201790551A1 (ru) | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору |
| WO2016132760A1 (ja) * | 2015-02-17 | 2016-08-25 | サンノプコ株式会社 | バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法 |
| US10973925B2 (en) | 2015-04-28 | 2021-04-13 | University Of Central Florida Research Foundation Inc. | Methods and compositions for theranostic nanoparticles |
| RS65941B1 (sr) | 2016-03-11 | 2024-10-31 | Cartesian Therapeutics Inc | Formulacije i doze pegilovane urikaze |
| KR102341902B1 (ko) * | 2016-09-09 | 2021-12-21 | 카오카부시키가이샤 | 디카르복실산 결정 및 그 제조 방법 |
| CN109922819A (zh) | 2016-09-27 | 2019-06-21 | 西莱克塔生物科技公司 | 用于治疗癌症的重组免疫毒素 |
| JP2020506890A (ja) | 2017-01-07 | 2020-03-05 | セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | 合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与 |
| EP4599848A3 (en) | 2017-03-11 | 2025-12-03 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
| KR20210119416A (ko) * | 2019-01-24 | 2021-10-05 | 제너레이션 바이오 컴퍼니 | 폐쇄-말단 dna (cedna), 및 유전자 또는 핵산 치료 관련 면역 반응을 감소시키는 방법에서의 이의 용도 |
| CA3138525A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
| CA3141863A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
| US20210154324A1 (en) * | 2019-10-21 | 2021-05-27 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
| IL292770A (en) | 2019-11-08 | 2022-07-01 | Selecta Biosciences Inc | Formulations and dosages of polyethylene glycol-modified oricase |
| MX2022010568A (es) | 2020-02-26 | 2022-11-30 | Selecta Biosciences Inc | Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor. |
| CA3174988A1 (en) * | 2020-03-11 | 2021-09-16 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
| KR20230002613A (ko) | 2020-04-14 | 2023-01-05 | 셀렉타 바이오사이언시즈, 인크. | 자가포식을 유도하기 위한 방법 및 조성물 |
| MX2023005224A (es) | 2020-11-04 | 2023-07-18 | Selecta Biosciences Inc | Composiciones para reducir las respuestas inmunes contra inmunoglobulina proteasas. |
| AU2022206197A1 (en) | 2021-01-05 | 2023-07-13 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| KR102304785B1 (ko) | 2021-03-26 | 2021-09-24 | (주)진성티앤피 | 정밀광학기기의 부품 제조 방법 |
| KR20230167405A (ko) | 2021-04-09 | 2023-12-08 | 셀렉타 바이오사이언시즈, 인크. | 면역 관용을 증진시키기 위해 고친화도 il-2 수용체 효능제와 조합된 면역억제제를 포함하는 합성 나노담체 |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| US20230140196A1 (en) | 2021-10-12 | 2023-05-04 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| WO2023086615A1 (en) | 2021-11-14 | 2023-05-19 | Selecta Biosciences, Inc. | Multiple dosing with viral vectors |
| US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| WO2023172628A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| WO2023196566A1 (en) | 2022-04-08 | 2023-10-12 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| JP2025526816A (ja) | 2022-08-11 | 2025-08-15 | カーティザン セラピューティクス，インコーポレーテッド | 免疫グロブリンプロテアーゼおよびその融合体に関する組成物および方法 |
| WO2024107889A1 (en) | 2022-11-15 | 2024-05-23 | Selecta Biosciences, Inc. | Compositions and methods for treating primary biliary cholangitis |
| WO2024229432A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| WO2024229370A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Compositions and methods for treating gvhd |
| WO2024229380A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases |
| WO2024229350A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes |
| TWI877967B (zh) * | 2023-12-28 | 2025-03-21 | 訊聯生物科技股份有限公司 | 包含小分子核糖核酸及奈米載體之組合物、包含其的醫藥組成物及其用途 |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| US5759830A (en) | 1986-11-20 | 1998-06-02 | Massachusetts Institute Of Technology | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| US7288266B2 (en) | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| JP2002521423A (ja) | 1998-07-31 | 2002-07-16 | コリア インスティチュート オブ サイエンス アンド テクノロージ | 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子 |
| DE69930753D1 (de) * | 1998-09-01 | 2006-05-18 | Elan Corp Plc Dublin | Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu |
| MXPA02008361A (es) | 2000-02-28 | 2004-05-17 | Genesegues Inc | Sistema y metodo de encapsulacion de nanocapsulas. |
| WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| CA2495913A1 (en) | 2002-08-23 | 2004-03-04 | Medigene Oncology Gmbh | Non-vesicular cationic lipid formulations |
| CN1886100A (zh) * | 2003-11-14 | 2006-12-27 | 阿尔萨公司 | 基于表面活性剂的凝胶作为可注射的持续药物递送载体 |
| US20050260260A1 (en) | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
| CN101291658B (zh) * | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| US8414910B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| AU2009268923B2 (en) * | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| WO2010005726A2 (en) * | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| EA201100765A1 (ru) * | 2008-12-15 | 2012-04-30 | Бинд Биосаиэнсис | Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств |
| KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| JP6073788B2 (ja) * | 2010-09-14 | 2017-02-01 | ナノロジカ アクティエボラーグ | 難水溶性医薬及び化粧品有効成分のための過飽和送達媒体 |
| WO2012059936A1 (en) * | 2010-11-03 | 2012-05-10 | Padma Venkitachalam Devarajan | Pharmaceutical compositions for colloidal drug delivery |
| CN107320734A (zh) * | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| CN102793674B (zh) * | 2011-05-26 | 2014-11-26 | 澳门科技大学 | 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用 |
| US20150272885A1 (en) | 2011-10-14 | 2015-10-01 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| TWI439288B (zh) * | 2012-10-05 | 2014-06-01 | Univ China Medical | 藥用載體及其製備方法與用途 |
| CN102871966B (zh) * | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
-
2015
- 2015-11-05 AU AU2015342968A patent/AU2015342968B2/en active Active
- 2015-11-05 DK DK15798601.9T patent/DK3215133T3/da active
- 2015-11-05 HU HUE15857076A patent/HUE054894T2/hu unknown
- 2015-11-05 LT LTEP15798601.9T patent/LT3215133T/lt unknown
- 2015-11-05 BR BR122021025344-7A patent/BR122021025344B1/pt active IP Right Grant
- 2015-11-05 IL IL296246A patent/IL296246A/en unknown
- 2015-11-05 ES ES21156943T patent/ES2977259T3/es active Active
- 2015-11-05 ES ES20204014T patent/ES2977158T3/es active Active
- 2015-11-05 KR KR1020177014830A patent/KR102656139B1/ko active Active
- 2015-11-05 BR BR112017008720A patent/BR112017008720A2/pt not_active Application Discontinuation
- 2015-11-05 FI FIEP20204014.3T patent/FI3834823T3/fi active
- 2015-11-05 FI FIEP21156943.9T patent/FI3906918T3/fi active
- 2015-11-05 KR KR1020177014831A patent/KR102601922B1/ko active Active
- 2015-11-05 AU AU2015342969A patent/AU2015342969B2/en active Active
- 2015-11-05 CN CN201580059855.4A patent/CN107072964A/zh active Pending
- 2015-11-05 EP EP23220853.8A patent/EP4360633A3/en not_active Withdrawn
- 2015-11-05 HR HRP20210098TT patent/HRP20210098T1/hr unknown
- 2015-11-05 IL IL295292A patent/IL295292B2/en unknown
- 2015-11-05 EP EP15857076.2A patent/EP3215192B1/en active Active
- 2015-11-05 DK DK20204014.3T patent/DK3834823T3/da active
- 2015-11-05 DK DK15857076.2T patent/DK3215192T3/da active
- 2015-11-05 EA EA201790977A patent/EA201790977A1/ru unknown
- 2015-11-05 ES ES15798601T patent/ES2846809T3/es active Active
- 2015-11-05 MX MX2017005903A patent/MX383295B/es unknown
- 2015-11-05 CN CN202210754573.8A patent/CN115212187A/zh active Pending
- 2015-11-05 EA EA201790978A patent/EA201790978A1/ru unknown
- 2015-11-05 HU HUE20204014A patent/HUE066099T2/hu unknown
- 2015-11-05 HU HUE15798601A patent/HUE053094T2/hu unknown
- 2015-11-05 WO PCT/US2015/059349 patent/WO2016073798A1/en not_active Ceased
- 2015-11-05 WO PCT/US2015/059350 patent/WO2016073799A1/en not_active Ceased
- 2015-11-05 PL PL15798601T patent/PL3215133T3/pl unknown
- 2015-11-05 CA CA2966852A patent/CA2966852C/en active Active
- 2015-11-05 HU HUE21156943A patent/HUE067697T2/hu unknown
- 2015-11-05 CN CN202210754468.4A patent/CN115212186A/zh active Pending
- 2015-11-05 MX MX2017005904A patent/MX386982B/es unknown
- 2015-11-05 ES ES15857076T patent/ES2865375T3/es active Active
- 2015-11-05 JP JP2017524451A patent/JP7218089B2/ja active Active
- 2015-11-05 CN CN201580060789.2A patent/CN107072965B/zh active Active
- 2015-11-05 IL IL283699A patent/IL283699B/en unknown
- 2015-11-05 US US14/934,135 patent/US20160128987A1/en not_active Abandoned
- 2015-11-05 RS RS20210097A patent/RS61359B1/sr unknown
- 2015-11-05 US US14/934,132 patent/US20160128986A1/en active Pending
- 2015-11-05 EP EP23220845.4A patent/EP4356910A3/en not_active Withdrawn
- 2015-11-05 CA CA2966850A patent/CA2966850C/en active Active
- 2015-11-05 BR BR112017008499-6A patent/BR112017008499B1/pt active IP Right Grant
- 2015-11-05 EP EP21156943.9A patent/EP3906918B1/en active Active
- 2015-11-05 DK DK21156943.9T patent/DK3906918T3/da active
- 2015-11-05 PT PT157986019T patent/PT3215133T/pt unknown
- 2015-11-05 EP EP20204014.3A patent/EP3834823B1/en active Active
- 2015-11-05 EP EP15798601.9A patent/EP3215133B1/en active Active
- 2015-11-05 SI SI201531494T patent/SI3215133T1/sl unknown
- 2015-11-05 CN CN202110403075.4A patent/CN113244191A/zh active Pending
- 2015-11-05 JP JP2017524450A patent/JP6912377B2/ja active Active
-
2017
- 2017-04-06 IL IL251620A patent/IL251620B/en active IP Right Grant
- 2017-04-06 IL IL251622A patent/IL251622B/en active IP Right Grant
- 2017-05-04 MX MX2021006698A patent/MX2021006698A/es unknown
- 2017-05-04 MX MX2021012273A patent/MX2021012273A/es unknown
-
2021
- 2021-01-27 CY CY20211100063T patent/CY1124418T1/el unknown
- 2021-01-31 IL IL280518A patent/IL280518B/en unknown
- 2021-05-10 JP JP2021080003A patent/JP7827412B2/ja active Active
- 2021-07-27 AU AU2021209202A patent/AU2021209202B2/en active Active
- 2021-07-27 AU AU2021209204A patent/AU2021209204A1/en not_active Abandoned
- 2021-12-02 IL IL288609A patent/IL288609B2/en unknown
-
2022
- 2022-09-01 JP JP2022139392A patent/JP2022173236A/ja active Pending
-
2023
- 2023-07-03 JP JP2023109379A patent/JP2023169893A/ja active Pending
-
2024
- 2024-10-21 US US18/921,868 patent/US20250152561A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021143180A5 (enExample) | ||
| FI3834823T3 (fi) | Menetelmiä ja koostumuksia liittyen alhaisen hlb:n omaavien pinta-aktiivisten aineiden käyttöön rapalogin käsittävien synteettisten nanokantajien valmistuksessa | |
| JP2017537081A5 (enExample) | ||
| Mao et al. | Effects of process and formulation parameters on characteristics and internal morphology of poly (d, l-lactide-co-glycolide) microspheres formed by the solvent evaporation method | |
| Li et al. | A review of the structure, preparation, and application of NLCs, PNPs, and PLNs | |
| Safwat et al. | Nanostructured lipid carriers loaded with simvastatin: effect of PEG/glycerides on characterization, stability, cellular uptake efficiency and in vitro cytotoxicity | |
| Sarmento et al. | Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system | |
| Wadhwa et al. | Emulsion forming drug delivery system for lipophilic drugs | |
| JP2010533714A5 (enExample) | ||
| US9907758B2 (en) | Process for preparing solid lipid sustained release nanoparticles for delivery of vitamins | |
| Garg et al. | Colloidal drug delivery systems: current status and future directions | |
| CN103040724B (zh) | 含聚合物与磷脂的纳米载药系统及其制备方法 | |
| Muthu et al. | Solubilized delivery of paliperidone palmitate by D-alpha-tocopheryl polyethylene glycol 1000 succinate micelles for improved short-term psychotic management | |
| Pathak et al. | Lipid nanocarriers: influence of lipids on product development and pharmacokinetics | |
| Sri Rekha et al. | Solid lipid nanoparticles: a potential option for enhancing oral bioavailability of highly soluble and poorly permeable (BCS Class III) drugs | |
| Jain et al. | In vitro and ex vivo evaluations of lipid anti-cancer nanoformulations: insights and assessment of bioavailability enhancement | |
| Ghosh et al. | A detailed insight into nanostructured lipid carriers: a versatile drug delivery system | |
| Bazzo et al. | Microspheres prepared with biodegradable PHBV and PLA polymers as prolonged-release system for ibuprofen: in vitro drug release and in vivo evaluation | |
| KR102089737B1 (ko) | 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법 | |
| Sulaiman et al. | Preparation and characterization of olmesartan medoxomil-loaded polymeric mixed micelle nanocarrier | |
| US20160081964A1 (en) | Oral pharmaceutical composition of isotretinoin | |
| Dhanaraju et al. | Preparation of poly (epsilon-caprolactone) microspheres containing etoposide by solvent evaporation method | |
| CN101961320A (zh) | 布地奈德纳米结晶制剂及其制备方法 | |
| TWI483747B (zh) | 口服式藥物載體及其製備方法 | |
| Gao et al. | In-vitro evaluation of paclitaxel-loaded MPEG–PLGA nanoparticles on laryngeal cancer cells |